Medicus Pharma (MDCX) Stock: Buy, Sell, or Hold?
MDCX - Medicus Pharma Ltd. Common Stock
$2.50
-0.12 (-4.58%)
▼
5d:
-23.08%
30d:
+1474.31%
90d:
+685.67%
WAIT
LOW Confidence
Analysis Updated: Oct 23, 2026 12:00 AM ET
Earnings: Nov 13, 2026
17d
Get Alerted When MDCX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
⏸️ WAIT FOR STABILIZATION: MDCX is down 23.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
⏸️ WAIT FOR STABILIZATION: MDCX is down 23.1% over the last 5 days. While fundamentals may be solid, catching a falling knife is risky. Wait for price to stabilize before entering.
In-depth Analysis How we analyze
Valuation Analysis: MDCX is currently trading at $2.50, which is considered slightly high relative to its 30-day fair value range of $-0.18 to $2.59.
Technical Outlook: Technically, MDCX is in a uptrend. The price is currently testing key support at $2.50. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.6% recently.
Market Sentiment: MDCX scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $203.75 (+8050.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, MDCX is in a uptrend. The price is currently testing key support at $2.50. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.6% recently.
Market Sentiment: MDCX scores 0/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $203.75 (+8050.0%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
SLIGHTLY HIGH
Historical Trading Range
$-0.18 -
$2.59
Company Quality Score
30/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
36.8%
All Signals
- BEARISH: Weak technical setup (0/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.6%)
- BULLISH: Trading 8050.0% below Wall St target ($203.75)
- WARNING: Composite score 30/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$-0.18 -
$2.59
Current vs Trading Range
SLIGHTLY HIGH
Support & Resistance Levels
Support Level
$2.50
Resistance Level
$4.69
Current Trend
Uptrend
Technical data as of
Oct 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-0.18
Wall Street Target
$203.75
(+8050.0%)
Share & Embed Analysis
Last updated: October 26, 2026 12:23 AM ET
Data refreshes hourly during market hours. Next update: 1:23 AM
Data refreshes hourly during market hours. Next update: 1:23 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is MDCX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
ABBV
AbbVie Inc |
STRONG BUY
30 analysts |
$285 | 45 HOLD |
|
LLY
Eli Lilly and Company |
STRONG BUY
31 analysts |
$1332 | 33 SELL |
|
MRK
Merck & Company Inc |
STRONG BUY
27 analysts |
$160 | 56 HOLD |
|
GILD
Gilead Sciences Inc |
STRONG BUY
28 analysts |
$160 | 41 HOLD |
|
BIIB
Biogen Inc |
BUY
36 analysts |
$247 | 43 HOLD |
